Viper has completed over $4 billion in deals outside of the cardiology space, and now has several surgical cardiology and subspecialty groups under contract.
Viper plans to enter the industry due to a low concentration of private equity in cardiology, an aging population and new changes to Medicare and Medicaid rules.
“We have been watching this area for a couple years and feel the time is perfect to bring our experience to this exciting space,” Samir Qureshi, Viper’s vice president, said in a Jan. 19 press release.
